AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) Receive the FDA's Accelerated Approval for HER-2 Positive Unresectable/ Metastatic Breast Cancer
Shots:
- The accelerated approval is based on P-II DESTINY-Breast01 study assessing Enhertu (5.4mg/kg) as monothx. in 184 patients with HER2-positive mBC- prior treated with two or more anti-HER2 based regimens in the metastatic setting at 100+ sites globally
- The P-II DESTINY-Breast01 study results: ORR (60.3%); CR (4.3%); PR (56.0%); mDOR (14.8mos. as of Aug 01- 2019); mPFS (16.4mos.)
- Enhertu is a HER2-directed ADC- currently being evaluated in three ongoing P-III studies for exploring its potential in other indications. The regulatory submission has been made to the MHLW based on DESTINY-Breast01 and P-I studies
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com